Celldex
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Perryville Iii Building suite 220 53 Fro...Phone Number
(908) 454-7120Website
www.celldex.comRevenue
<$5 MillionStock Symbol
CLDXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Celldex
Founded in 1983, Celldex Therapeutics is a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care. They are based in Hampton, New Jersey.Explore more
Celldex Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Celldex your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Celldex, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Celldex had a recent Job posting/layoffs
Check out if Celldex is spiking on competitors!
Product Launch: Get notified when Celldex launches new products
Earning: See what the market has to say on Celldex recently announced quarterly report
Check if Celldex has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Celldex has new funding data
Congratulate Masked Content for being promoted to Masked Content at Celldex
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Celldex as Masked Content
Find 2 more new buyers
Compare Similar Companies to Celldex
Compare insights from companies similar to Celldex, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$462.1M
1994
TC
Tracy ClementeChief People Officer & Chief Human Resources Officer
Company Profile Activity
Activity Insights
Celldex is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Celldex is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Celldex.
Celldex Tech Stack
A closer look at the technologies used by Celldex
See more technologies
Most Recent Scoops
Project
Celldex has initiated a Phase III study of barzolvolimab in two forms of inducible urticaria, following Phase II results that demonstrated clinical benefit including high rates of complete response and improvements in quality of life. The study was initiated in late 2025, with enrollment currently underway.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Celldex has reported first-in-human data for CDX-622, a novel bispecific antibody combining mast cell depletion and TSLP inhibition, demonstrating rapid, durable, dose-dependent reductions in serum tryptase and a well-tolerated safety profile across all doses. Currently being studied in asthma, CDX-622 is planned for additional proof-of-concept studies in allergic rhinitis and food allergies.
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Celldex News & Media
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented positive results from the Phase 1 healthy participant study of CDX-622, a novel, bispecific antibody that targets soluble SCF and TSLP, at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. Data demonstrated that CDX-622 induced rapid, durable, dose-dependent reductions in serum tryptase, indicative of mast cell depletion, and was well-tolerated at all dose levCelldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria -- -- Late-breaking poster presentation on CDX-622 -- HAMPTON, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that three presentations from the barzolvolimab and CDX-622 programs will be shared at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress being held in Istanbul, Türkiye, on June 12-15, 2026.Celldex Reports First Quarter Financial Results and Provides Corporate Update
HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment
Celldex Therapeutics (NASDAQ:CLDX) executives used an appearance at H.C. Wainwright’s annual Inflammation and Skin Disease Conference to highlight the company’s late-stage plans for barzolvolimab, an anti-KIT monoclonal antibody being developed for chronic urticaria and other inflammatory skin disea
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Celldex
Sign Up For FreeTo access detailed company insights
Founded in 1983, Celldex Therapeutics is a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care. They are based in Hampton, New Jersey.... Read More
